2019

Danese MD, Katz A, Cetin K, Chia V, Gleeson ML, Kelsh M, et al. 2019. Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data. Leuk Lymphoma 60(8):2015–2024.

View Abstract

Danese MD, Katz A, Cetin K, Chia V, Gleeson ML, Kelsh M, et al. 2019. Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: An observational cohort study using SEER Medicare data. Leuk Lymphoma 60(8):2015–2024.

View Abstract

Bylsma LC, Dean RGK, Lowe K, Sangaré L, Alexander D, Fryzek J. 2019. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics. Cancer Med 8(12):5800-5809; doi: 10.1002/cam4.2413.

View Abstract

Sacks NC, Sharma A, Cyr PL, Stong L, Dahdal DN. Real-world evidence comparison of colorectal cancer screening outcomes with different colorectal cancer preparation agents in adults 65 years and older. Digestive Disease Week Annual Meeting, San Diego, May 2019.

Hathway J, Jensen IS, Cyr PL, Koshy, TI, Parks, P, Weinstein MC. Economic analysis of colorectal cancer screening from multiple stakeholder perspectives: Key components to improve practical applications in the US. ISPOR 24th Annual International Meeting, New Orleans LA, 2019.

Bylsma LC, Levin-Sparenberg E, Lowe K, Sangare L, Fryzek J, Alexander DD. Prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer (MCRC) patients: A systematic literature review and meta-analysis. Poster presented as part of a Spotlight Poster Session at the International Society for Pharmacoepidemiology, Philadelphia, PA, August 2019.

2018

Beebe-Dimmer JL, Ruterbusch JJ, Bylsma LC, Gillezeau C, Fryzek J, Schultz NM, Flanders SC, Barlev A, Heath E, Quek RGW. 2018. Patterns of bicalutamide use in prostate cancer treatment: A U.S. real-world analysis using the SEER-Medicare database. Adv Ther 35(1):1438-1451.

View Abstract

Schwartz KL, Simon MS, Bylsma LC, Ruterbusch JJ, Beebe-Dimmer JL, Schultz NM,  Flanders SC, Barlev A, Fryzek JP, Quek RGW. 2018. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States. Cancer 124(10):2104-2114.

View Abstract

Bylsma LC, Gillezeau C, Garawin T, Kelsh M, Fryzek J, Sangare L, Lowe KA. Prevalence of RAS and BRAF mutations in Metastatic Colorectal Cancer (mCRC) patients by tumor location. Presented at the Gastrointestinal Cancers Symposium, San Francisco, CA, January 2018.

Fryzek JP, Reichert H, Summers N, Townes L, Deuson R, Alexander DD, Vanderpuye-Orgle J. 2018. Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen. PLoS One 13(4):e0195790.

View Abstract